enGene to Participate in the Leerink Partners Global Healthcare Conference
enGene Holdings (Nasdaq: ENGN), a clinical-stage, non-viral genetic medicines company, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference. Ron Cooper, Chief Executive Officer, will engage in a fireside chat at the conference, which is scheduled for Tuesday, March 11, 2025, at 1:00 p.m. ET in Miami, FL.
Interested parties can access a live webcast of the presentation through the 'Investors' section of enGene's website at www.engene.com. The webcast recording will remain available on the website for 90 days following the event.
enGene Holdings (Nasdaq: ENGN), una società di medicina genetica non virale in fase clinica, ha annunciato la sua partecipazione alla prossima Global Healthcare Conference di Leerink Partners. Ron Cooper, Amministratore Delegato, parteciperà a una chiacchierata informale durante la conferenza, che si terrà martedì 11 marzo 2025, alle 13:00 ET a Miami, FL.
Le parti interessate possono accedere a una trasmissione in diretta della presentazione attraverso la sezione 'Investitori' del sito web di enGene all'indirizzo www.engene.com. La registrazione della trasmissione rimarrà disponibile sul sito per 90 giorni dopo l'evento.
enGene Holdings (Nasdaq: ENGN), una empresa de medicamentos genéticos no virales en etapa clínica, ha anunciado su participación en la próxima Conferencia Global de Salud de Leerink Partners. Ron Cooper, Director Ejecutivo, participará en una charla informal en la conferencia, que está programada para martes, 11 de marzo de 2025, a la 1:00 p.m. ET en Miami, FL.
Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección 'Inversores' del sitio web de enGene en www.engene.com. La grabación de la transmisión estará disponible en el sitio durante 90 días después del evento.
enGene Holdings (Nasdaq: ENGN), 임상 단계의 비바이러스 유전자 의약품 회사가 다가오는 Leerink Partners 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. Ron Cooper CEO가 컨퍼런스에서 2025년 3월 11일 화요일 오후 1시 ET에 마이애미, FL에서 진행되는 대화에 참여할 예정입니다.
관심 있는 분들은 enGene 웹사이트의 '투자자' 섹션을 통해 발표의 라이브 웹캐스트에 접속할 수 있습니다. 웹캐스트 녹화는 행사 후 90일 동안 웹사이트에서 이용 가능합니다.
enGene Holdings (Nasdaq: ENGN), une entreprise de médicaments génétiques non viraux en phase clinique, a annoncé sa participation à la prochaine Conférence Mondiale sur la Santé de Leerink Partners. Ron Cooper, Directeur Général, participera à une discussion informelle lors de la conférence, prévue pour mardi 11 mars 2025 à 13h00 ET à Miami, FL.
Les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section 'Investisseurs' du site web d'enGene à l'adresse www.engene.com. L'enregistrement du webinaire restera disponible sur le site pendant 90 jours après l'événement.
enGene Holdings (Nasdaq: ENGN), ein Unternehmen für nicht-virale genetische Medikamente in der klinischen Phase, hat seine Teilnahme an der bevorstehenden Leerink Partners Global Healthcare Conference angekündigt. Ron Cooper, Chief Executive Officer, wird an einem informellen Gespräch auf der Konferenz teilnehmen, die für Dienstag, den 11. März 2025, um 13:00 Uhr ET in Miami, FL, geplant ist.
Interessierte Parteien können über den Bereich 'Investoren' auf der Website von enGene unter www.engene.com auf einen Live-Stream der Präsentation zugreifen. Die Aufzeichnung des Webcasts bleibt 90 Tage nach der Veranstaltung auf der Website verfügbar.
- None.
- None.
A live webcast of the fireside chat can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days.
About enGene
enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 study, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.
To learn more, please visit enGene.com and follow us on LinkedIn, X and
View source version on businesswire.com: https://www.businesswire.com/news/home/20250304286014/en/
For media contact:
908-577-4531
mediainquiries@grcomms.com
For investor contact:
investors@engene.com
Source: enGene Holdings Inc.
FAQ
When and where is enGene (ENGN) presenting at the Leerink Partners Conference 2025?
How can investors watch enGene's (ENGN) presentation at the Leerink Partners Conference?
What type of presentation will ENGN deliver at the Leerink Partners Healthcare Conference?
What is enGene's (ENGN) primary business focus?
